Skip to main content

Volume 9 Supplement 3

Proceedings of the 2007 and 2008 Drug Discovery for Neurodegeneration Conference


Edited by Howard Fillit and Antony Horton

The conference and the publication of these proceedings were supported by a conference grant: U13-AG031125 from the National Institute of Aging and the National Institute for Neurological Disorders and Stroke. Additional support was provided by CoMentis, Inc; Pfizer, Inc.; Biogen Idec and Boehringer Ingelheim Pharmaceuticals, Inc.

2007 and 2008 Drug Discovery for Neurodegeneration Conference. Go to conference site.

New York, USA. 5-6 February 2007Washington, DC, USA. 4-5 February 2008

  1. Intranasal delivery provides a practical, non-invasive method of bypassing the blood-brain barrier (BBB) to deliver therapeutic agents to the brain and spinal cord. This technology allows drugs that do not cro...

    Authors: Leah R Hanson and William H Frey II
    Citation: BMC Neuroscience 2008 9(Suppl 3):S5
  2. This short review outlines the rationale, challenges, and opportunities for intranasal acetylcholinesterases, in particular galantamine. An in vitro screening model facilitated the development of a therapeuticall...

    Authors: Henry R Costantino, Alexis Kays Leonard, Gordon Brandt, Paul H Johnson and Steven C Quay
    Citation: BMC Neuroscience 2008 9(Suppl 3):S6

Annual Journal Metrics

Sign up for article alerts and news from this journal